Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)

Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially dangerous food impaction. Standard treatments include proton pump inhibitors (PPIs) and topical steroids. Recently, new therapies have emerged, such as Takeda’s Eohilia (budesonide oral suspension), approved in 2024, and Sanofi / Regeneron’s Dupixent (dupilumab), approved by the FDA in 2022. Other promising treatments in the pipeline include tezepelumab (AstraZeneca), cendakimab (Bristol Myers Squibb), and APT-1011 (Ellodi Pharmaceuticals). As the EoE treatment landscape evolves, this report offers insight from real-world claims data into prescribing trends in EoE to help developers better understand current treatment and define the market niche for emerging products.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed EoE patients?
• What are the quarterly trends in prescribing among recently treated and newly diagnosed EoE patients? How has Dupixent been integrated into the treatment algorithm?
• What percentage of EoE patients receive drug therapy within one year of diagnosis, and how quickly?
• What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of EoE patients are treated with monotherapy vs. combination therapy? What are the most used combinations?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: Sanofi / Regeneron, Takeda

Key drugs: PPIs (e.g., omeprazole, pantoprazole, esomeprazole), topical glucocorticoids (e.g., fluticasone propionate), oral / systemic glucocorticoids (e.g., prednisone), Dupixent (dupilumab), Eohilia (budesonide oral suspension)

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.